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BACKGROUND
● Testicular Germ Cell Tumors (TGCT) are the most common 
cancer in young men
● Most patients are successfully treated with a combination of 
cisplatin, bleomycin and etoposide
● TGCT derive from aberrantly arrested fetal gonocytes
● However, 15-20% of patients are refractory to cisplatin 
treatment or undergo late relapse
● Refractory TGCT are highly sensitive to DNA methylation 
inhibitor
● 5-aza treatment demethylates the hypermethylated CpG 
islands in TGCT
ABSTRACT
Testicular germ cell tumors (TGCT) are the most common type of cancer in 
young men. Patients are successfully treated with a combination of cisplatin, 
bleomycin, and etoposide. However, 15-20% of patients are refractory to 
cisplatin treatment or undergo late relapse. We have previously shown that 
these refractory TGCT cells are highly sensitive to the DNA 
methyltransferase inhibitor, 5-aza deoxycytidine (5-aza). However, the 
mechanism is unknown. Recent studies suggest that 5-aza targets certain 
types of cancer cells, like colorectal and ovarian, by inducing the viral 
mimicry pathway. We hypothesize the mechanism of 5-aza hypersensitivity 
in TGCT cells is due to hyperactivation of immune surveillance pathways 
including the endogenous retroviral (ERV) dsRNA MDA5/MAVS/IRF7 
pathway. We demonstrate that interferon stimulated genes are induced with 
5-aza treatment in TGCT cell lines. However, silencing MAVS and TLR3 of 
the viral mimicry pathway did not inhibit the antitumor effects of 5-aza. The 
results demonstrate that 5-aza hypersensitivity in TGCT is not due to 
hyperactivation of immune surveillance pathways, but the pathway may be 
necessary for the survival of TGCT cells. For future studies, we will explore 
the use of 5-aza treatment and the blockage of the viral mimicry pathway as 
a treatment of TGCT.
AIM
To determine whether the mechanism of 5-aza hypersensitivity in 
TGCT cells is due to hyperactivation of immune surveillance pathways 
including the endogenous retroviral dsRNA MDA5/MAVS/IRF7 
pathway seen in colorectal and ovarian cancer.
• Experiment 1: Assess whether components of viral mimicry 
pathway and downstream interferon stimulated genes are induced 
in response to 5-Aza treatment
• Experiment 2: Knocking down core components of viral mimicry 
pathway and assess anticancer effects of 5-Aza in EC cells
RESULTS
➢ Interferon stimulated genes are induced with 5-aza treatment in 
EC cell lines
➢ Silencing shRNA validation
➢ Silencing antiviral sensors does not block the antitumor effects of 
5-aza 
CONCLUSION
● 5-Aza hypersensitivity in TGCT cells is not due to hyper-
activation of immune surveillance pathways,  but the 
pathway may be  necessary for the survival of the TGCT 
cells
FUTURE DIRECTIONS
● Overexpressing the components of the viral mimicry 
pathway to determine any anticancer effecty of 5-Aza in 
EC cells
● Knockdown of the components of the viral mimicry 
pathway in an in vivo model to assess any pro-survival 
effects of TGCT
Ema Khan, Jennifer Rodriguez, Emmanuel Bikorimana and Michael Spinella
Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois.
Determining the Mechanism of 5-aza Hypersensitivity in Testicular Germ Cell Tumors 
MATERIALS & METHODS
Cell culture and drug treatments. NT2 cells were cultured in DMEM 
media with 10% fetal bovine serum supplemented with glutamine and 
antibiotics. Cells were treated with indicated dosages of 5-aza for 
three consecutive days and drug was replenished each day.
Cell viability. Cell-Titre Glo assay was performed.
Real-time PCR and immunoblot analyses. cDNA with SYBER 
green was used for real-time PCR and data was analyzed using the 
ddCT method normalized to GAPDH. For western blot analyses, cells 
were lysed with RIPA and separated by SDS-PAGE. Immunoblotted 
with indicated antibodies in the results section.
Lentiviral production. Stable cell lines were produced by transducing 
NT2 cells with silencing shRNAs targeting either MAVS or TLR3. 
PLKO.1 empty vector was used as a control. 
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• DNA-demethylating agents target colorectal cancer cells by 
inducing viral mimicry by endogenous transcripts (Roulois et al,. 
2015, cell 162, 961-973)
• Inhibiting DNA methylation causes an interferon response in 
cancer via dsRNA including endogenous retroviruses (Chiappinelli
et al., 2015, cell 162, 974-986)
• Vitamin C increases viral mimicry induced by 5-aza-2’ 
deoxycytidine (liu et al., 2016, PNAs 113, 10238-10244)
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